Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models.
Paolo F CaimiJan Joseph MelenhorstPublished in: Cancer immunology research (2024)
All chimeric antigen receptor (CAR) T-cell products currently approved by the FDA are autologous, which poses several challenges for widespread use. In this issue, Degagné and colleagues present their preclinical research on creating off-the-shelf CAR T cells for multiple myeloma. They utilized the CRISPR/Cas12a genome editing platform and gene knock-in techniques to eliminate alloreactivity and decrease susceptibility to natural killer (NK)-cell elimination. This work has led to an ongoing phase I trial of off-the-shelf CAR T cells for multiple myeloma treatment. See related article by Degagné et al., p. 462 (2).
Keyphrases
- crispr cas
- genome editing
- multiple myeloma
- cell therapy
- nk cells
- bone marrow
- induced apoptosis
- stem cell transplantation
- clinical trial
- stem cells
- cell cycle arrest
- mesenchymal stem cells
- single cell
- study protocol
- phase iii
- high throughput
- phase ii
- copy number
- oxidative stress
- randomized controlled trial
- cell death
- endoplasmic reticulum stress
- dna methylation
- open label
- hematopoietic stem cell
- smoking cessation
- replacement therapy